A Phase 4 interventional study of Placebo plus standard therapy and Belimumab 10 mg/kg plus standard therapy in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Completed at 250 sites in 33 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-15.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one has the largest enrollment, is one of 5 that started in 2012, is one of 10 in phase 4, and was the 18th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
National University Hospital, Singapore · Sites in Singapore
Ages 21–70
First Affiliated Hospital Xi'an Jiaotong University
Ages 18+
By country, each count listing its studies:
belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,019 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 81 across the 36 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one has the largest enrollment of the 36 interventional ones that give a count, is one of 8 that started in 2012, is one of 5 in phase 4, and was the 23rd registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
2 of the studies testing belimumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, from their registry updates:
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to further enhance the existing knowledge regarding the side effects of belimumab when given with other lupus medicines to adults with active systemic lupus erythematosus (SLE). This study mainly focuses on collecting information on serious events that are not that common or may only be seen with long-term treatment. These events include death, serious infections and other infections of interest, cancers, serious mental health problems, including depression and suicide, and serious infusion and hypersensitivity reactions. This study is being done to help understand if treatment with belimumab increases the risk for these types of events. This study will also see if patients receiving belimumab with other lupus medicines can reduce their use of steroids, such as prednisone, over 1 year.
Study participants receive standard therapy for SLE in addition to receiving the study drug, either placebo (no active medicine) or belimumab. The controlled period of the study is 52 weeks. The random assignment in this study is "1 to 1" which means that participants have an equal chance of receiving belimumab or placebo. After completion of the 52-week study period, participants will be contacted by phone annually for 4 more years to assess health status.
Following the 52-week controlled period, participants who wish to continue treatment with belimumab may be able to do so by being prescribed commercially available belimumab. If belimumab is not commercially available in the participant's country, the participant may be able to receive belimumab under a separate continuation protocol.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.
Biological: Placebo plus standard therapy · Other: Standard therapy
Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.
Biological: Belimumab 10 mg/kg plus standard therapy · Other: Standard therapy
Placebo plus standard therapy
Drug page: Belimumab
Belimumab 10 mg/kg plus standard therapy
Also known as: BENLYSTA™
Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.
Number of Deaths - On Treatment Period (Week 52)
Number of participants who died during on-treatment period (Week 52) is reported. The on-treatment period was defined as first dose to last dose + 28 days (or death). The As-Treated Population was defined as all participants who were randomized and received at least one dose of study agent,grouped according to the actual treatment administered for the majority (greater than \[\>\]50 percent \[%\]) of the time. The on-treatment period was the primary analysis period for safety analyses.
Time frame: Up to Week 52 (On-treatment period)
Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52)
A summary of protocol defined AESIs including serious infections, opportunistic infections and other infections of interest (serious and non-serious), non-melanoma skin cancer (NMSC), malignancies (excluding NMSC), psychiatric events suggesting serious mood disorders and anxiety (serious depression), suicidality (using Columbia-Suicide Severity Rating Scale \[C-SSRS\]) and serious infusion and hypersensitivity reactions (SIHR) is reported. The on-treatment period (Week 52) was defined as first dose to last dose + 28 days (or death). The on-treatment period was the primary analysis period for safety analyses.
Time frame: Up to Week 52 (On-treatment period)
Number of Participants With Serious Adverse Events (SAEs) Reported During On-treatment Period (Week 52)
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement. The on-treatment period (Week 52) was defined as first dose to last dose + 28 days (or death) and was the primary analysis period for safety analyses.
Time frame: Up to Week 52 (On-treatment period)
Number of Deaths Reported - On-study Period (Week 52)
Number of participants who died during on-study period (Week 52) is reported. The on-study period (which includes on and off treatment data) was defined as first dose to the end of the Week 52 study follow-up (or death). The on-study period was a supportive analysis period for safety analysis.
Time frame: Up to Week 52 (On-study period)
Number of Participants Who Reported Protocol Defined AESI: On-study Period (Week 52)
A summary of protocol defined AESIs including serious infections, opportunistic infections and other infections of interest (serious and non-serious), NMSC, malignancies (excluding NMSC), psychiatric events suggesting serious mood disorders and anxiety (serious depression), suicidality (using C-SSRS) and SIHR is reported. The on-study period (Week 52) (which includes on and off treatment data) was defined as first dose to the end of the Week 52 study follow-up (or death). The on-study period was a supportive analysis period for safety analysis.
Time frame: Up to Week 52 (On-study period)
Number of Participants With SAEs Reported During On-study Period (Week 52)
A SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement. The on-study period (Week 52) (which includes on and off treatment data) was defined as first dose to the end of the Week 52 study follow-up (or death) and was a supportive analysis period for safety analyses.
Time frame: Up to Week 52 (On-study period)
Percentage of Participants Whose Average Prednisone (or Equivalent) Dose to Treat SLE Has Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52
The average daily prednisone dose during Weeks 40 to 52 is the sum of all prednisone doses to treat SLE from the day following the Week 40 visit date up to but not including the Week 52 study completion date divided by the number of days between Week 40 visit date and study completion date (study completion date - Week 40 visit date). Percentage of participants whose average prednisone dose has been reduced by \>=25% from Baseline to \<=7.5 mg/day during Weeks 40 through 52 in participants with average prednisone use greater than 7.5 mg/day at Baseline was compared between belimumab and placebo using a logistic regression model including treatment group, Baseline prednisone dose, screening safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score (\<=9 versus \>=10) and region. Baseline is defined as the last available value measured prior to dosing on or before the date of first dose (Day 1).
Time frame: Week 40 to Week 52
Number of Participants With All-cause Mortality During Years 2 to 5
Number of participants with all-cause mortality during years 2 to 5 has been presented.
Time frame: From 2 years to 5 years
Number of Participants With New Primary Malignancies During Years 2 to 5
Number of participants with new primary malignancies during years 2 to 5 has been presented.
Time frame: From 2 years to 5 years
This was a global, multi-center, randomized, placebo-controlled double blind study that evaluated adverse events of special interest in adult participants with active, autoantibody-positive systemic lupus erythematosus (SLE) when treated with belimumab plus standard therapy versus participants who received placebo plus standard therapy for 1 year, followed by a Year 2-5 post-treatment follow-up period.
| Milestone | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Started | 2009 | 2010 |
| Intent-to-treat population | 2002 | 2001 |
| Completed | 1729 | 1741 |
| Not completed | 280 | 269 |
| Withdrew: Withdrawal by subject | 128 | 128 |
| Withdrew: Adverse event | 57 | 49 |
| Withdrew: Protocol violation | 2 | 4 |
| Withdrew: Site closure | 3 | 2 |
| Withdrew: Lost to follow-up | 33 | 37 |
| Withdrew: Physician decision | 48 | 38 |
| Withdrew: Missing study conclusion form | 2 | 2 |
| Withdrew: Randomized but not treated | 7 | 9 |
| Milestone | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Started | 1670 | 1695 |
| Completed | 1474 | 1514 |
| Not completed | 196 | 181 |
| Withdrew: Death | 58 | 38 |
| Withdrew: Lost to follow-up | 75 | 89 |
| Withdrew: Withdrawal by subject | 44 | 36 |
| Withdrew: Missing | 19 | 18 |
Number of participants who died during on-treatment period (Week 52) is reported. The on-treatment period was defined as first dose to last dose + 28 days (or death). The As-Treated Population was defined as all participants who were randomized and received at least one dose of study agent,grouped according to the actual treatment administered for the majority (greater than \[\>\]50 percent \[%\]) of the time. The on-treatment period was the primary analysis period for safety analyses.
| Participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Number of Deaths - On Treatment Period (Week 52) | 8 | 10 |
A summary of protocol defined AESIs including serious infections, opportunistic infections and other infections of interest (serious and non-serious), non-melanoma skin cancer (NMSC), malignancies (excluding NMSC), psychiatric events suggesting serious mood disorders and anxiety (serious depression), suicidality (using Columbia-Suicide Severity Rating Scale \[C-SSRS\]) and serious infusion and hypersensitivity reactions (SIHR) is reported. The on-treatment period (Week 52) was defined as first dose to last dose + 28 days (or death). The on-treatment period was the primary analysis period for safety analyses.
| Participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Serious Infections, n=2001, 2002 | 82 | 75 |
| Opportunistic Infections and Other Infections of Interest, n=2001, 2002 | 50 | 36 |
| Malignancies (Excluding NMSC), n=2001, 2002 | 5 | 5 |
| NMSC, n=2001, 2002 | 3 | 4 |
| Psychiatric Events Suggesting Serious Mood Disorders and Anxiety (Serious depression), n=2001, 2002 | 1 | 7 |
| Suicidality (C-SSRS), n=1986, 1972 | 23 | 28 |
| SIHR, n=2001, 2002 | 2 | 8 |
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement. The on-treatment period (Week 52) was defined as first dose to last dose + 28 days (or death) and was the primary analysis period for safety analyses.
| Participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) Reported During On-treatment Period (Week 52) | 222 | 220 |
Number of participants who died during on-study period (Week 52) is reported. The on-study period (which includes on and off treatment data) was defined as first dose to the end of the Week 52 study follow-up (or death). The on-study period was a supportive analysis period for safety analysis.
| Participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Number of Deaths Reported - On-study Period (Week 52) | 22 | 13 |
A summary of protocol defined AESIs including serious infections, opportunistic infections and other infections of interest (serious and non-serious), NMSC, malignancies (excluding NMSC), psychiatric events suggesting serious mood disorders and anxiety (serious depression), suicidality (using C-SSRS) and SIHR is reported. The on-study period (Week 52) (which includes on and off treatment data) was defined as first dose to the end of the Week 52 study follow-up (or death). The on-study period was a supportive analysis period for safety analysis.
| Participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Serious Infections, n=2001, 2002 | 95 | 80 |
| Opportunistic Infections and Other Infections of Interest, n=2001, 2002 | 59 | 39 |
| Malignancies (Excluding NMC), n=2001, 2002 | 7 | 5 |
| NMSC, n=2001, 2002 | 3 | 4 |
| Psychiatric Events Suggesting Serious Mood Disorders and Anxiety (Serious depression), n=2001, 2002 | 1 | 7 |
| Suicidality (C-SSRS), n=1988, 1974 | 25 | 31 |
| SIHR, n=2001, 2002 | 2 | 8 |
A SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement. The on-study period (Week 52) (which includes on and off treatment data) was defined as first dose to the end of the Week 52 study follow-up (or death) and was a supportive analysis period for safety analyses.
| Participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Number of Participants With SAEs Reported During On-study Period (Week 52) | 241 | 233 |
The average daily prednisone dose during Weeks 40 to 52 is the sum of all prednisone doses to treat SLE from the day following the Week 40 visit date up to but not including the Week 52 study completion date divided by the number of days between Week 40 visit date and study completion date (study completion date - Week 40 visit date). Percentage of participants whose average prednisone dose has been reduced by \>=25% from Baseline to \<=7.5 mg/day during Weeks 40 through 52 in participants with average prednisone use greater than 7.5 mg/day at Baseline was compared between belimumab and placebo using a logistic regression model including treatment group, Baseline prednisone dose, screening safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score (\<=9 versus \>=10) and region. Baseline is defined as the last available value measured prior to dosing on or before the date of first dose (Day 1).
| Percentage of Participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Percentage of Participants Whose Average Prednisone (or Equivalent) Dose to Treat SLE Has Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 | 16.2 | 19.9 |
Number of participants with all-cause mortality during years 2 to 5 has been presented.
| Participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Number of Participants With All-cause Mortality During Years 2 to 5 | 58 | 38 |
Number of participants with new primary malignancies during years 2 to 5 has been presented.
| Participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Number of Participants With New Primary Malignancies During Years 2 to 5 | 22 | 24 |
Collected over AESIs and all SAEs were collected up to Week 52 (On-study period), all-cause mortality was collected up to end of study (up to 5 years). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 80/2,001 (4%) | 241/2,001 (12%) | 31/2,001 (1.5%) |
| Belimumab 10 mg/kg | 51/2,002 (2.5%) | 233/2,002 (11.6%) | 17/2,002 (0.8%) |
| Event | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| PneumoniaInfections and infestations | 27/2001 | 18/2002 |
| Urinary tract infectionInfections and infestations | 8/2001 | 16/2002 |
| Lupus nephritisRenal and urinary disorders | 11/2001 | 6/2002 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 11/2001 | 5/2002 |
| GastroenteritisInfections and infestations | 11/2001 | 4/2002 |
| CellulitisInfections and infestations | 8/2001 | 7/2002 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 7/2001 | 2/2002 |
| Acute kidney injuryRenal and urinary disorders | 6/2001 | 2/2002 |
| PyrexiaGeneral disorders | 6/2001 | 2/2002 |
| Suicidal ideationPsychiatric disorders | 2/2001 | 6/2002 |
| Event | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Herpes zosterInfections and infestations | 31/2001 | 17/2002 |
Baseline characteristics were reported for ITT Population.
| Age, Continuous(Years) | Placebo | Belimumab 10 mg/kg | Total |
|---|---|---|---|
| Mean | 40.8 ± 12.74 | 40.4 ± 12.75 | 40.6 ± 12.74 |
| Sex: Female, Male(Participants) | Placebo | Belimumab 10 mg/kg | Total |
|---|---|---|---|
| Female | 1853 | 1848 | 3701 |
| Male | 149 | 153 | 302 |
| Race/Ethnicity, Customized(Participants) | Placebo | Belimumab 10 mg/kg | Total |
|---|---|---|---|
| White/Caucasian-European Heritage | 1070 | 1080 | 2150 |
| White/Caucasian-Arabic/North African Heritage | 19 | 16 | 35 |
| Mixed White Race | 1 | 0 | 1 |
| Asian-East Asian Heritage | 310 | 307 | 617 |
| Asian-South East Asian Heritage | 172 | 168 | 340 |
| Asian-Central/South Asian Heritage | 8 | 6 | 14 |
| Asian-Japanese Heritage | 2 | 1 | 3 |
| Mixed Asian Race | 0 | 1 | 1 |
| African American/African Heritage | 155 | 175 | 330 |
| Alaskan Native or American Indian | 257 | 228 | 485 |
| Native Hawaiian or Other Pacific Islander | 2 | 5 | 7 |
| Missing | 6 | 14 | 20 |
Showing the first 100 of 250 sites across 33 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Nov 2012 to primary completion in Jul 2018, 68 months.
Results were first posted in Nov 2019, 1 year 3 months after primary completion.
Of 33 phase 4 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 42. This study's 68 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Lupus Erythematosus, Systemic →